BMS-986369

DRUG4 trials

Sponsors

Bristol-Myers Squibb, Celgene

Conditions

Healthy ParticipantsHealthy VolunteerHealthy VolunteersHepatic ImpairmentRelapsed or Refractory T-cell Lymphomas

Phase 1

A Study to Evaluate the Drug Exposure of Single Ascending Doses of BMS-986369 and the Effect of Food on the BMS-986369 in Healthy Participants

CompletedNCT05350800

Bristol-Myers SquibbHealthy Volunteer

Start: 2022-09-12End: 2023-05-04Updated: 2024-07-05

A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants

CompletedNCT05567510

Bristol-Myers SquibbHealthy Participants

Start: 2022-10-20End: 2022-12-27Updated: 2023-02-17

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Active, not recruitingNCT06035497

Bristol-Myers SquibbRelapsed or Refractory T-cell Lymphomas

Start: 2023-11-20End: 2030-10-10Target: 85Updated: 2026-05-01

Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

CompletedNCT06535399

CelgeneHealthy Volunteers, Hepatic Impairment

Start: 2024-08-15End: 2025-11-12Updated: 2026-01-23

Related Papers

Trial in Progress: Phase 1/2 Study of Cereblon-Modulating Agent Golcadomide (BMS-986369/CC-99282) in Relapsed or Refractory (R/R) T-Cell Lymphomas (TCLs) (GOLSEEK-3)

Blood2024-11-051 citations